Retrophin (RTRX) Tops Q3 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Retrophin Reports Third Quarter 2017 Financial Results
November 7, 2017 4:21 PM ESTSAN DIEGO, CALIFORNIA -- (Marketwired) -- 11/07/17 -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2017 financial results and provided a corporate update.
-- The Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase- associated neurodegeneration (PKAN) remains on-track to complete enrollment in the second half of 2018 -- The Company received regulatory feedback on its Phase 3 protocol for sparsentan in FSGS; additional statistical analyses to be provided while trial start-up activities continue -- Net product sales for the third quarter of 2017 were $40.3 million, compared to $33.9 million for the same period in 2016 -- Cash, cash equivalents and... More